Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%) ...

The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...

Explore how community oncology reduces financial toxicity in cancer care, highlighting cost savings and quality benefits over ...

The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, patients received the agent via subcutaneous injection every three weeks ...

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...

HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...

The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...

In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...

Explore the complexities of HPV status in head and neck cancer treatment, emphasizing the importance of accurate patient ...